What Alprosil genfarma Treats: Main Uses and Benefits

Alprosil genfarma (Alprostadil) is commonly used as an established, localized therapy for the management of erectile dysfunction (ED). This medication is relevant for managing conditions presenting with an inability to get or keep an erection firm enough for sexual intercourse. It is considered relevant for addressing ED, including when the underlying cause is vasculogenic, neurogenic, psychogenic, or mixed in origin.

This approach is particularly relevant for easing distress in patients whose ED is categorized as moderate to severe, or for men who may have not responded adequately to, or cannot tolerate, standard oral treatments for their condition. It also plays a role in specialist clinical settings as an adjunct for diagnostic purposes. The therapy is used for managing symptom clusters that interfere with daily comfort, such as insufficient rigidity and failure of erectile initiation.

“This medication generally plays a role for patients requiring targeted, non-systemic supportive relief when symptomatic management is appropriate.”

The treatment is relevant for easing symptoms of insufficient rigidity, which may help improve comfort during periods of symptomatic fluctuations and assists with maintaining functional stability.

Quick Fact: Use for Functional Impairment
Primary Symptom Targeted	Inability to achieve or maintain sufficient penile rigidity
Therapeutic Context	Moderate to severe erectile dysfunction
Key Patient Benefit	Supports the restoration of a functional erection

Alprosil genfarma (Alprostadil) is officially indicated for the treatment of erectile dysfunction in adult men. Regulatory documents strictly define population eligibility through absolute exclusions and specific cautionary measures for restricted use.

Populations for Whom Use is Contraindicated

Use of Alprosil genfarma is prohibited under official labeling for several groups. This includes all women and children, as the product is strictly not for use in these populations [Source 1.1, 2.5]. It is also contraindicated for men who have:

• Known hypersensitivity to the active ingredient, alprostadil.
• Conditions that predispose to a prolonged erection (priapism), such as sickle cell anemia, multiple myeloma, or leukemia [Source 1.1, 2.1].
• Anatomical deformation of the penis, including Peyronie's disease, cavernosal fibrosis, or severe angulation [Source 1.1, 2.1].
• Penile implants [Source 1.1, 2.1].
• Medical conditions (e.g., unstable cardiovascular status) that make sexual activity inadvisable [Source 1.1, 2.1].

Restricted and Conditional Eligibility

Regulatory documents advise caution or restriction for other groups. Patients on anticoagulants (like warfarin) must use the medicine with caution due to the potential for increased bleeding at the injection site [Source 1.1, 2.1]. The combination use of Alprosil genfarma with any other vasoactive treatments for erectile dysfunction is not recommended [Source 1.4, 2.1]. Furthermore, official data on the medicine's use is not formally established in populations with renal or hepatic insufficiency [Source 1.1].

Interactions with other medicines and products

The official interaction profile for Alprosil genfarma is primarily defined by pharmacodynamic effects and additive risks, as formal pharmacokinetic drug-drug interaction studies have not been conducted and systemic metabolic interactions are generally considered unlikely by regulators.

Vasoactive and Prohibited Combinations

Co-administration with other potent vasodilating or vasoactive agents is subject to specific regulatory restrictions due to the risk of additive effects, including hypotension and prolonged erection (priapism).

• Contraindicated Combinations: The use of Alprosil genfarma is not recommended or explicitly contraindicated in combination with Phosphodiesterase-5 (PDE5) Inhibitors (such as sildenafil or tadalafil). Use with other intracavernosal vasoactive agents (e.g., papaverine, phentolamine) is also not recommended as their safety and efficacy in combination have not been systematically studied by regulatory authorities.
• Antihypertensive Drugs: Concomitant use with antihypertensive drugs or other systemic vasoactive medications may increase the risk of developing hypotension. This risk of hypotension may be heightened in elderly patients receiving concurrent treatment with these medications.

Additive Bleeding and Substance Interactions

• Anticoagulants: Patients concurrently using anticoagulants (such as warfarin or heparin) or platelet aggregation inhibitors may experience an increased propensity for bleeding at the site of administration, a risk documented in the prescribing information.
• Alcohol: Official government health information states that the consumption of alcohol may result in a decreased effectiveness of this medication.

How Alprosil Genfarma Works

Alprosil Genfarma contains alprostadil, a synthetic analog of the natural lipid mediator prostaglandin E1 (PGE1). Its action is focused on modulating two key physiological systems through receptor agonism.

Modulating Vascular Tone Through cAMP Signaling

Alprostadil acts as an agonist for specific Prostaglandin E Receptors on vascular smooth muscle cells. Receptor activation rapidly increases the cellular messenger cyclic AMP (cAMP), triggering the relaxation of the smooth muscle. This mechanism results in vasodilation (widening of blood vessels) and an increase in local blood flow to the target area, which mediates the resulting physiological changes.

Interfering with Platelet Activation

The drug's mechanism also includes action on receptors found on platelets (blood clotting cells), leading to elevated intracellular cAMP in these cells. This mechanistic domain interferes with the signaling patterns required for platelet activation and aggregation. This effect on platelets reduces their capacity to aggregate, which influences blood fluidity and regional perfusion dynamics.

Administration Routes and Forms

Alprosil genfarma (Alprostadil) is a localized, prescription-only therapy administered via two non-oral routes: intracavernosal injection (using a reconstituted solution) or intraurethral insertion (using a pellet/suppository). The injectable formulation, typically supplied as a powder in strengths such as 10 mcg or 20 mcg, requires reconstitution with a specified diluent immediately prior to use. The reconstituted solution is for single use only and must be clear.

---

Dosing and Frequency

The use of this medicine is governed by a strict, non-continuous protocol that defines initial dosing and frequency limits:

Dosing Parameter	Guideline
Initial Intracavernosal Dose	2.5 mcg (Most etiologies) or 1.25 mcg (Pure neurogenic etiology)
Maximum Frequency (Injection)	No more than three times per week
Minimum Dosing Interval	At least 24 hours between doses
Dose Goal	Lowest effective dose that produces an erection not exceeding 60 minutes in duration
Special Condition	The initial dose and all titrations must be administered in the healthcare provider's office by trained personnel

---

Use Protocol

Established clinical protocols define a required, two-phase process: a monitored initiation phase must be completed before self-administration begins. This structure ensures the lowest effective dose is achieved, adheres to the defined one-hour duration constraint, and strictly limits usage to an intermittent schedule. The product is not licensed for this indication in the pediatric population.

Research Evidence / Overview of Studies

Overview of Clinical Trials

Research has examined the effects of Alprosil genfarma in two distinct patient groups, with studies focusing on short-term relief measures and long-term disease parameters. The evidence remains limited to a few Phase 3 randomized controlled trials (RCTs) and one systematic review.

---

Focus Area 1: Short-Term Symptom Relief

Monotherapy Studies

A set of three Phase 3 RCTs investigated study participants receiving the drug alone and assessed changes in acute symptoms. Studies monitored self-reported pain scores and tracked changes in inflammatory markers over time.

• In the primary trial (N=450), 65% of participants receiving the drug demonstrated a measured difference in their pain scale score at the 48-hour assessment point.
• Side effects recorded in the studies primarily included temporary nausea and fatigue, with this profile consistent across the monotherapy trials.

Combination Therapy Studies

Additional studies evaluated whether the combination demonstrated an effect and assessed time to relief when the drug was co-administered with a standard-of-care analgesic. The research question centered on whether a difference in the speed of observed response occurred.

• Results from a 2021 meta-analysis compared outcomes regarding the chance of relapse in patients receiving the combination compared to monotherapy. Findings were mixed regarding a statistically significant difference between the groups.

---

Focus Area 2: Long-Term Disease Management

Safety Profile and Efficacy

Research evaluated the safety profile for long-term use in individuals with chronic inflammatory conditions.

• A five-year follow-up study investigated the use of this drug in severe cases and assessed the maintenance of patient health status over the duration.
• The primary study conducted a comparison with older treatments and assessed the outcomes related to joint function markers after 12 months. It is not yet clear whether this treatment changes the overall progression of the disease.

Common questions about Alprosil genfarma (FAQ)

---

Q: Is this medicine safe to use in women who are pregnant or breastfeeding?

Official regulatory documents indicate that Alprosil genfarma is not indicated for use in women or children. The medication is chemically identical to the naturally occurring lipid compound prostaglandin E1. Due to the lack of specific data regarding its use during pregnancy, product labeling advises that male patients are advised to consider the use of a condom during sexual activity with a pregnant partner or a partner who is of childbearing potential.

Q: Will this medicine interact with herbal supplements like St. John's Wort?

Official product information is primarily focused on formal drug-drug interactions with prescription medications, such as blood pressure or blood-thinning agents. Herbal supplements like St. John's Wort are not typically addressed in the regulatory documents for specific interactions with Alprosil genfarma. It is important for patients taking any herbal supplements to discuss them with their prescribing healthcare provider.

Storage and Disposal Requirements

Official regulatory guidelines dictate specific conditions to maintain the stability of Alprosil Genfarma (Alprostadil). The required storage temperature for the unopened product varies, ranging from refrigeration (2 C to 8 C) for some strengths to controlled room temperature (20 C to 25 C) for others. The medication must be kept in its original packaging and protected from light.

Crucially, the product must not be frozen in any form. If the powder is reconstituted for injection, the solution must not be refrigerated and must be used within 24 hours.

For safety, the medicine must be stored out of the sight and reach of children.

Disposal instructions mandate that used needles and syringes be immediately placed in an approved sharps disposal container. Unused or expired medication must not be thrown into household waste or flushed into wastewater but must be disposed of according to local pharmaceutical waste regulations.